[Mizolastine improves the quality of life in patients with perennial allergic rhinitis: a randomized, double blind, controlled study].
OBJECTIVE
To assess the effect of Mizolastine on quality of life (QOL) in patients with perennial allergic rhinitis.


METHODS
A randomized, double-blind, placebo-controlled study was carried out with Mizolastine in sixty patients with perennial allergic rhinitis. QOL was measured by using the Medical Outcome Study Short-Form Health Survey (SF-36) questionnaire (Chinese version). Mizolastine (10 mg once daily, 26 patients), Cetirizine (10 mg once daily, 22 patients) or placebo (12 patients) was given for 3 weeks. The SF-36 questionnaire was administered at the start of treatment and after 1 and 3 weeks of treatment. Symptom-medication scores were measured daily during the study.


RESULTS
After the run-in period (baseline), there were no significant differences among the Mezolastine, Cetirizine and placebo groups in terms of symptoms or QOL scores. After 1 and 3 weeks of treatment, symptoms scores were significantly decreased and QOL scores significantly improved in the Mezolastine group and Cetirizine group in comparison with the placebo group ( both P < 0.001, chi2 test). All of the eight QOL dimensions were significantly improved (from P = 0.001 to P < 0.0001, F test) after 1 and 3 weeks of Mizolastine treatment compared with placebo. There was no improvement in the placebo group.


CONCLUSIONS
Mizolastine can not only decrease symptoms scores but also improve the QOL in patients with perennial allergic rhinitis. Placebo can relieve the symptoms but can not improve the QOL.
Wang
Hong-Tian
HT
Department of Otorhinolaryngology Head and Neck Surgery, General Hospital of Chinese People's Liberation Army, Beijing 100853, China. wanght@plagh.com.cn
Zhou
Hai-Ting
HT
Song
Jun-Zhi
JZ
Han
Dong-Yi
DY
Wang
Rong-Guang
RG
D000293:Adolescent; D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D055815:Young Adult
D001562:Benzimidazoles; C076170:mizolastine